bluebird bio, Inc. (BLUE) Can’t Be More Risky. The Stock Formed a Bearish H&S Pattern

July 14, 2018 - By Ash Ash

bluebird bio, Inc. (NASDAQ:BLUE) Logo

Investors sentiment decreased to 0.99 in 2018 Q1. Its down 0.52, from 1.51 in 2017Q4. It dropped, as 34 investors sold bluebird bio, Inc. shares while 91 reduced holdings. 46 funds opened positions while 78 raised stakes. 51.45 million shares or 1.46% more from 50.71 million shares in 2017Q4 were reported.
California Public Employees Retirement Sys stated it has 0.02% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Clearbridge Invs Ltd Limited Liability Company has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). The Florida-based Eagle Asset Mngmt Inc has invested 0.21% in bluebird bio, Inc. (NASDAQ:BLUE). Advisory Ltd Com invested in 110 shares. Frontier Capital Mngmt Co Lc reported 51,481 shares or 0.06% of all its holdings. Affinity Advsr Limited Liability has 0.05% invested in bluebird bio, Inc. (NASDAQ:BLUE). Morgan Stanley has invested 0.02% in bluebird bio, Inc. (NASDAQ:BLUE). Lpl Fincl Limited Liability Company holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 5,199 shares. 25,335 are held by Fund Mngmt. Mackay Shields Ltd Liability Corporation owns 0.02% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 14,655 shares. 7,262 are held by Twin Tree Management L P. Td Asset Mngmt Inc stated it has 47,186 shares or 0.01% of all its holdings. Los Angeles Management Equity holds 0.02% or 17,716 shares in its portfolio. Parametric Portfolio Limited Liability Corporation invested 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Great West Life Assurance Can has 5,531 shares for 0% of their portfolio.

The stock of bluebird bio, Inc. (BLUE) formed H&S with $164.35 target or 9.00 % below today’s $180.60 share price. The 6 months Head & Shoulders indicates high risk for the $9.05 billion company. It was reported on Jul, 14 by If the $164.35 price target is reached, the company will be worth $814.68 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.17% or $0.3 during the last trading session, reaching $180.6. About 487,131 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 135.78% since July 14, 2017 and is uptrending. It has outperformed by 123.21% the S&P500.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on August, 1. They expect $-2.32 earnings per share, down 34.10 % or $0.59 from last year’s $-1.73 per share. After $-2.31 actual earnings per share reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts 0.43 % negative EPS growth.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 15 analysts covering bluebird bio (NASDAQ:BLUE), 8 have Buy rating, 1 Sell and 6 Hold. Therefore 53% are positive. bluebird bio has $250.0 highest and $113.0 lowest target. $219.17’s average target is 21.36% above currents $180.6 stock price. bluebird bio had 25 analyst reports since January 25, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, March 5 by William Blair. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Hold” rating given on Wednesday, May 2 by Oppenheimer. The rating was maintained by Jefferies with “Buy” on Thursday, February 22. As per Friday, June 1, the company rating was maintained by BTIG Research. As per Monday, February 26, the company rating was maintained by Morgan Stanley. The firm earned “Equal-Weight” rating on Wednesday, March 21 by Morgan Stanley. As per Wednesday, March 28, the company rating was maintained by Oppenheimer. PiperJaffray reinitiated it with “Overweight” rating and $240 target in Thursday, May 31 report. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Hold” rating given on Friday, June 15 by Oppenheimer. On Tuesday, June 19 the stock rating was upgraded by Evercore to “Outperform”.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: which released: “Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives” on June 23, 2018, also with their article: “bluebird bio (BLUE) Notes Partner Celgene (CELG) Amends Dose Range for Phase 2 Study of bb2121” published on July 12, 2018, published: “Gabelli Starts bluebird bio (BLUE) at Buy (Earlier)” on July 12, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: and their article: “Why bluebird bio’s Shares Have Tumbled 11.9% in 2018 So Far” published on July 08, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: June 19, 2018.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington. The company has market cap of $9.05 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. It currently has negative earnings. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.